nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyproheptadine—Haemolytic anaemia—Mechlorethamine—lymphatic system cancer	0.0231	0.0231	CcSEcCtD
Cyproheptadine—Haemolytic anaemia—Teniposide—lymphatic system cancer	0.0171	0.0171	CcSEcCtD
Cyproheptadine—Jaundice—Mechlorethamine—lymphatic system cancer	0.0157	0.0157	CcSEcCtD
Cyproheptadine—Neuritis—Vincristine—lymphatic system cancer	0.0153	0.0153	CcSEcCtD
Cyproheptadine—Hepatic failure—Fludarabine—lymphatic system cancer	0.0151	0.0151	CcSEcCtD
Cyproheptadine—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.015	0.015	CcSEcCtD
Cyproheptadine—Tinnitus—Mechlorethamine—lymphatic system cancer	0.0135	0.0135	CcSEcCtD
Cyproheptadine—Wheezing—Bleomycin—lymphatic system cancer	0.0133	0.0133	CcSEcCtD
Cyproheptadine—Neuropathy peripheral—Teniposide—lymphatic system cancer	0.0116	0.0116	CcSEcCtD
Cyproheptadine—Sweating increased—Fludarabine—lymphatic system cancer	0.0114	0.0114	CcSEcCtD
Cyproheptadine—Vertigo—Mechlorethamine—lymphatic system cancer	0.0113	0.0113	CcSEcCtD
Cyproheptadine—Leukopenia—Mechlorethamine—lymphatic system cancer	0.0113	0.0113	CcSEcCtD
Cyproheptadine—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.0102	0.0102	CcSEcCtD
Cyproheptadine—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Cyproheptadine—Anorexia—Mechlorethamine—lymphatic system cancer	0.00979	0.00979	CcSEcCtD
Cyproheptadine—Chills—Teniposide—lymphatic system cancer	0.00956	0.00956	CcSEcCtD
Cyproheptadine—Hepatic failure—Vincristine—lymphatic system cancer	0.0092	0.0092	CcSEcCtD
Cyproheptadine—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00893	0.00893	CcSEcCtD
Cyproheptadine—Diplopia—Carmustine—lymphatic system cancer	0.00866	0.00866	CcSEcCtD
Cyproheptadine—Agitation—Teniposide—lymphatic system cancer	0.00852	0.00852	CcSEcCtD
Cyproheptadine—Chills—Fludarabine—lymphatic system cancer	0.0084	0.0084	CcSEcCtD
Cyproheptadine—Leukopenia—Teniposide—lymphatic system cancer	0.0083	0.0083	CcSEcCtD
Cyproheptadine—Urinary retention—Vincristine—lymphatic system cancer	0.00786	0.00786	CcSEcCtD
Cyproheptadine—Confusional state—Teniposide—lymphatic system cancer	0.00763	0.00763	CcSEcCtD
Cyproheptadine—Oedema—Teniposide—lymphatic system cancer	0.00757	0.00757	CcSEcCtD
Cyproheptadine—Agitation—Fludarabine—lymphatic system cancer	0.00749	0.00749	CcSEcCtD
Cyproheptadine—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00741	0.00741	CcSEcCtD
Cyproheptadine—Tachycardia—Teniposide—lymphatic system cancer	0.00739	0.00739	CcSEcCtD
Cyproheptadine—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00732	0.00732	CcSEcCtD
Cyproheptadine—Leukopenia—Fludarabine—lymphatic system cancer	0.0073	0.0073	CcSEcCtD
Cyproheptadine—Anorexia—Teniposide—lymphatic system cancer	0.00722	0.00722	CcSEcCtD
Cyproheptadine—Hypotension—Teniposide—lymphatic system cancer	0.00707	0.00707	CcSEcCtD
Cyproheptadine—Convulsion—Fludarabine—lymphatic system cancer	0.00706	0.00706	CcSEcCtD
Cyproheptadine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00703	0.00703	CcSEcCtD
Cyproheptadine—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00678	0.00678	CcSEcCtD
Cyproheptadine—Confusional state—Fludarabine—lymphatic system cancer	0.00671	0.00671	CcSEcCtD
Cyproheptadine—Oedema—Fludarabine—lymphatic system cancer	0.00665	0.00665	CcSEcCtD
Cyproheptadine—Decreased appetite—Teniposide—lymphatic system cancer	0.00658	0.00658	CcSEcCtD
Cyproheptadine—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00654	0.00654	CcSEcCtD
Cyproheptadine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00653	0.00653	CcSEcCtD
Cyproheptadine—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00652	0.00652	CcSEcCtD
Cyproheptadine—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00651	0.00651	CcSEcCtD
Cyproheptadine—Rash—Mechlorethamine—lymphatic system cancer	0.00647	0.00647	CcSEcCtD
Cyproheptadine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00647	0.00647	CcSEcCtD
Cyproheptadine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00643	0.00643	CcSEcCtD
Cyproheptadine—Anorexia—Fludarabine—lymphatic system cancer	0.00634	0.00634	CcSEcCtD
Cyproheptadine—Weight increased—Mitoxantrone—lymphatic system cancer	0.00633	0.00633	CcSEcCtD
Cyproheptadine—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00625	0.00625	CcSEcCtD
Cyproheptadine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00624	0.00624	CcSEcCtD
Cyproheptadine—Drowsiness—Mitoxantrone—lymphatic system cancer	0.00621	0.00621	CcSEcCtD
Cyproheptadine—Chills—Bleomycin—lymphatic system cancer	0.00616	0.00616	CcSEcCtD
Cyproheptadine—Nausea—Mechlorethamine—lymphatic system cancer	0.0061	0.0061	CcSEcCtD
Cyproheptadine—Jaundice—Mitoxantrone—lymphatic system cancer	0.00605	0.00605	CcSEcCtD
Cyproheptadine—Urticaria—Teniposide—lymphatic system cancer	0.00601	0.00601	CcSEcCtD
Cyproheptadine—Paraesthesia—Fludarabine—lymphatic system cancer	0.00597	0.00597	CcSEcCtD
Cyproheptadine—Hallucination—Carmustine—lymphatic system cancer	0.00596	0.00596	CcSEcCtD
Cyproheptadine—Dyspepsia—Fludarabine—lymphatic system cancer	0.00586	0.00586	CcSEcCtD
Cyproheptadine—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00579	0.00579	CcSEcCtD
Cyproheptadine—Decreased appetite—Fludarabine—lymphatic system cancer	0.00578	0.00578	CcSEcCtD
Cyproheptadine—Fatigue—Fludarabine—lymphatic system cancer	0.00574	0.00574	CcSEcCtD
Cyproheptadine—Hallucination—Vincristine—lymphatic system cancer	0.00569	0.00569	CcSEcCtD
Cyproheptadine—Constipation—Fludarabine—lymphatic system cancer	0.00569	0.00569	CcSEcCtD
Cyproheptadine—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00557	0.00557	CcSEcCtD
Cyproheptadine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00548	0.00548	CcSEcCtD
Cyproheptadine—Asthenia—Teniposide—lymphatic system cancer	0.00543	0.00543	CcSEcCtD
Cyproheptadine—Leukopenia—Bleomycin—lymphatic system cancer	0.00535	0.00535	CcSEcCtD
Cyproheptadine—Diarrhoea—Teniposide—lymphatic system cancer	0.00518	0.00518	CcSEcCtD
Cyproheptadine—Chills—Mitoxantrone—lymphatic system cancer	0.005	0.005	CcSEcCtD
Cyproheptadine—Confusional state—Bleomycin—lymphatic system cancer	0.00492	0.00492	CcSEcCtD
Cyproheptadine—Vision blurred—Carmustine—lymphatic system cancer	0.00492	0.00492	CcSEcCtD
Cyproheptadine—Tremor—Carmustine—lymphatic system cancer	0.00489	0.00489	CcSEcCtD
Cyproheptadine—Oedema—Bleomycin—lymphatic system cancer	0.00488	0.00488	CcSEcCtD
Cyproheptadine—Vomiting—Teniposide—lymphatic system cancer	0.00481	0.00481	CcSEcCtD
Cyproheptadine—Agitation—Carmustine—lymphatic system cancer	0.00479	0.00479	CcSEcCtD
Cyproheptadine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00478	0.00478	CcSEcCtD
Cyproheptadine—Asthenia—Fludarabine—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Cyproheptadine—Rash—Teniposide—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Cyproheptadine—Dermatitis—Teniposide—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Cyproheptadine—Headache—Teniposide—lymphatic system cancer	0.00474	0.00474	CcSEcCtD
Cyproheptadine—Leukopenia—Carmustine—lymphatic system cancer	0.00467	0.00467	CcSEcCtD
Cyproheptadine—Anorexia—Bleomycin—lymphatic system cancer	0.00465	0.00465	CcSEcCtD
Cyproheptadine—Agitation—Vincristine—lymphatic system cancer	0.00458	0.00458	CcSEcCtD
Cyproheptadine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00457	0.00457	CcSEcCtD
Cyproheptadine—Photosensitivity—Methotrexate—lymphatic system cancer	0.00457	0.00457	CcSEcCtD
Cyproheptadine—Hypotension—Bleomycin—lymphatic system cancer	0.00456	0.00456	CcSEcCtD
Cyproheptadine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00455	0.00455	CcSEcCtD
Cyproheptadine—Convulsion—Carmustine—lymphatic system cancer	0.00452	0.00452	CcSEcCtD
Cyproheptadine—Nausea—Teniposide—lymphatic system cancer	0.0045	0.0045	CcSEcCtD
Cyproheptadine—Vertigo—Vincristine—lymphatic system cancer	0.00447	0.00447	CcSEcCtD
Cyproheptadine—Hepatic failure—Methotrexate—lymphatic system cancer	0.00446	0.00446	CcSEcCtD
Cyproheptadine—Leukopenia—Vincristine—lymphatic system cancer	0.00446	0.00446	CcSEcCtD
Cyproheptadine—Paraesthesia—Bleomycin—lymphatic system cancer	0.00438	0.00438	CcSEcCtD
Cyproheptadine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00434	0.00434	CcSEcCtD
Cyproheptadine—Convulsion—Vincristine—lymphatic system cancer	0.00431	0.00431	CcSEcCtD
Cyproheptadine—Confusional state—Carmustine—lymphatic system cancer	0.00429	0.00429	CcSEcCtD
Cyproheptadine—Oedema—Carmustine—lymphatic system cancer	0.00426	0.00426	CcSEcCtD
Cyproheptadine—Decreased appetite—Bleomycin—lymphatic system cancer	0.00424	0.00424	CcSEcCtD
Cyproheptadine—Vomiting—Fludarabine—lymphatic system cancer	0.00423	0.00423	CcSEcCtD
Cyproheptadine—Convulsion—Mitoxantrone—lymphatic system cancer	0.0042	0.0042	CcSEcCtD
Cyproheptadine—Rash—Fludarabine—lymphatic system cancer	0.00419	0.00419	CcSEcCtD
Cyproheptadine—Dermatitis—Fludarabine—lymphatic system cancer	0.00419	0.00419	CcSEcCtD
Cyproheptadine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00417	0.00417	CcSEcCtD
Cyproheptadine—Headache—Fludarabine—lymphatic system cancer	0.00417	0.00417	CcSEcCtD
Cyproheptadine—Tachycardia—Carmustine—lymphatic system cancer	0.00416	0.00416	CcSEcCtD
Cyproheptadine—Oedema—Vincristine—lymphatic system cancer	0.00406	0.00406	CcSEcCtD
Cyproheptadine—Anorexia—Carmustine—lymphatic system cancer	0.00406	0.00406	CcSEcCtD
Cyproheptadine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00402	0.00402	CcSEcCtD
Cyproheptadine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Cyproheptadine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Cyproheptadine—Hypotension—Carmustine—lymphatic system cancer	0.00398	0.00398	CcSEcCtD
Cyproheptadine—Oedema—Mitoxantrone—lymphatic system cancer	0.00396	0.00396	CcSEcCtD
Cyproheptadine—Nausea—Fludarabine—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Cyproheptadine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00393	0.00393	CcSEcCtD
Cyproheptadine—Shock—Mitoxantrone—lymphatic system cancer	0.00389	0.00389	CcSEcCtD
Cyproheptadine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00388	0.00388	CcSEcCtD
Cyproheptadine—Urticaria—Bleomycin—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Cyproheptadine—Anorexia—Vincristine—lymphatic system cancer	0.00387	0.00387	CcSEcCtD
Cyproheptadine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Cyproheptadine—Insomnia—Carmustine—lymphatic system cancer	0.00385	0.00385	CcSEcCtD
Cyproheptadine—Irritability—Methotrexate—lymphatic system cancer	0.00383	0.00383	CcSEcCtD
Cyproheptadine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00383	0.00383	CcSEcCtD
Cyproheptadine—Paraesthesia—Carmustine—lymphatic system cancer	0.00382	0.00382	CcSEcCtD
Cyproheptadine—Hypotension—Vincristine—lymphatic system cancer	0.0038	0.0038	CcSEcCtD
Cyproheptadine—Somnolence—Carmustine—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Cyproheptadine—Anorexia—Mitoxantrone—lymphatic system cancer	0.00377	0.00377	CcSEcCtD
Cyproheptadine—Decreased appetite—Carmustine—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Cyproheptadine—Hypotension—Mitoxantrone—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Cyproheptadine—Insomnia—Vincristine—lymphatic system cancer	0.00368	0.00368	CcSEcCtD
Cyproheptadine—Paraesthesia—Vincristine—lymphatic system cancer	0.00365	0.00365	CcSEcCtD
Cyproheptadine—Constipation—Carmustine—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Cyproheptadine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Cyproheptadine—Decreased appetite—Vincristine—lymphatic system cancer	0.00353	0.00353	CcSEcCtD
Cyproheptadine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00352	0.00352	CcSEcCtD
Cyproheptadine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00351	0.00351	CcSEcCtD
Cyproheptadine—Fatigue—Vincristine—lymphatic system cancer	0.0035	0.0035	CcSEcCtD
Cyproheptadine—Asthenia—Bleomycin—lymphatic system cancer	0.0035	0.0035	CcSEcCtD
Cyproheptadine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Cyproheptadine—Constipation—Vincristine—lymphatic system cancer	0.00348	0.00348	CcSEcCtD
Cyproheptadine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00344	0.00344	CcSEcCtD
Cyproheptadine—Fatigue—Mitoxantrone—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Cyproheptadine—Constipation—Mitoxantrone—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Cyproheptadine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00326	0.00326	CcSEcCtD
Cyproheptadine—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.00317	0.00317	CcSEcCtD
Cyproheptadine—Urticaria—Mitoxantrone—lymphatic system cancer	0.00314	0.00314	CcSEcCtD
Cyproheptadine—Vomiting—Bleomycin—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Cyproheptadine—Drowsiness—Methotrexate—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Cyproheptadine—Rash—Bleomycin—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Cyproheptadine—Dermatitis—Bleomycin—lymphatic system cancer	0.00307	0.00307	CcSEcCtD
Cyproheptadine—Asthenia—Carmustine—lymphatic system cancer	0.00305	0.00305	CcSEcCtD
Cyproheptadine—Asthenia—Vincristine—lymphatic system cancer	0.00292	0.00292	CcSEcCtD
Cyproheptadine—Diarrhoea—Carmustine—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Cyproheptadine—Nausea—Bleomycin—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Cyproheptadine—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00289	0.00289	CcSEcCtD
Cyproheptadine—Asthenia—Mitoxantrone—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Cyproheptadine—Dizziness—Carmustine—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Cyproheptadine—Diarrhoea—Vincristine—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Cyproheptadine—Hepatitis—Methotrexate—lymphatic system cancer	0.00278	0.00278	CcSEcCtD
Cyproheptadine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Cyproheptadine—Vomiting—Carmustine—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Cyproheptadine—Dizziness—Vincristine—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Cyproheptadine—Rash—Carmustine—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Cyproheptadine—Dermatitis—Carmustine—lymphatic system cancer	0.00268	0.00268	CcSEcCtD
Cyproheptadine—Headache—Carmustine—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Cyproheptadine—Tinnitus—Methotrexate—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Cyproheptadine—Vomiting—Vincristine—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Cyproheptadine—Rash—Vincristine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Cyproheptadine—Dermatitis—Vincristine—lymphatic system cancer	0.00256	0.00256	CcSEcCtD
Cyproheptadine—Headache—Vincristine—lymphatic system cancer	0.00255	0.00255	CcSEcCtD
Cyproheptadine—Nausea—Carmustine—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Cyproheptadine—Vomiting—Mitoxantrone—lymphatic system cancer	0.00252	0.00252	CcSEcCtD
Cyproheptadine—Rash—Mitoxantrone—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Cyproheptadine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Cyproheptadine—Chills—Methotrexate—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Cyproheptadine—Headache—Mitoxantrone—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Cyproheptadine—Nausea—Vincristine—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Cyproheptadine—Nausea—Mitoxantrone—lymphatic system cancer	0.00235	0.00235	CcSEcCtD
Cyproheptadine—Vision blurred—Methotrexate—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Cyproheptadine—Vertigo—Methotrexate—lymphatic system cancer	0.00217	0.00217	CcSEcCtD
Cyproheptadine—Leukopenia—Methotrexate—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Cyproheptadine—Convulsion—Methotrexate—lymphatic system cancer	0.00209	0.00209	CcSEcCtD
Cyproheptadine—Confusional state—Methotrexate—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Cyproheptadine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Cyproheptadine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Cyproheptadine—Anorexia—Methotrexate—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Cyproheptadine—Hypotension—Methotrexate—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Cyproheptadine—Insomnia—Methotrexate—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Cyproheptadine—Paraesthesia—Methotrexate—lymphatic system cancer	0.00177	0.00177	CcSEcCtD
Cyproheptadine—Somnolence—Methotrexate—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Cyproheptadine—Dyspepsia—Methotrexate—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Cyproheptadine—Decreased appetite—Methotrexate—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Cyproheptadine—Fatigue—Methotrexate—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Cyproheptadine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Cyproheptadine—Urticaria—Methotrexate—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Cyproheptadine—Asthenia—Methotrexate—lymphatic system cancer	0.00141	0.00141	CcSEcCtD
Cyproheptadine—Diarrhoea—Methotrexate—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Cyproheptadine—Dizziness—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Cyproheptadine—Vomiting—Methotrexate—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Cyproheptadine—Rash—Methotrexate—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Cyproheptadine—Dermatitis—Methotrexate—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Cyproheptadine—Headache—Methotrexate—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Cyproheptadine—Nausea—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
